RNAi for Therapeutic Market (Updated Version Available)

The report offers detailed coverage of RNAi for Therapeutic industry and main market trends. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading RNAi for Therapeutic by geography. The report splits the market size, by volume and value, on the basis of application type and geography.
RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after these apparently unrelated processes were fully understood did it become clear that they all described the RNAi phenomenon. RNAi is now known as precise, efficient, stable and better than antisense technology for gene suppression.
RNAi for Therapeutic is in the development stage and there is no use in the market. The fastest research is Clinical phrase III, Such as QP1-1007, QO1-1002 of Quark Pharmaceuticals. The major technology of RNAi for Therapeutic is siRNA, miRNA and shRNA. SiRNA technology is the most popular, with the expenses market share of 85%, following SiRNA, miRNA is the second of 16% expenses market share in 2015.
At present, global expenses concentrates in US and Europe, US takes 80% market share and Europe takes 5% market share. There is A Few R & D Company in the world and the market concentration is high. The top5 (expenses in RNAi for Therapeutic) companies are Alnylam Pharmaceuticals, Arrowhead, Dicerna Pharmaceuticals, Gradalis, miRagen Therapeutics. The five companies occupy about 83% of the market share.

The report forecast global RNAi for Therapeutic market to grow to reach xxx Million USD in 2020 with a CAGR of xx% during the period 2021-2025.

First, this report covers the present status and the future prospects of the global RNAi for Therapeutic market for 2015-2025.
And in this report, we analyze global market from 5 geographies: Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia], Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland], North America[United States, Canada, Mexico], Middle East & Africa[GCC, North Africa, South Africa], South America[Brazil, Argentina, Columbia, Chile, Peru].

Key Companies
Alnylam Pharmaceuticals
Arbutus Biopharma (Tekmira)
Arrowhead
Dicerna Pharmaceuticals
Mirna Therapeutics
Quark Pharmaceuticals
RXi Pharmaceuticals
Silence Therapeutics
Benitec Biopharma
miRagen Therapeutics
Sylentis
Gradalis
Sirnaomics
Silenseed


At the same time, we classify RNAi for Therapeutic according to the type, application by geography. More importantly, the report includes major countries market based on the type and application.

Market Segment as follows:
Market by Order Type
siRNA
miRNA
Market by Application
Cancer
Cardiovascular
HBV
Other

By Region
Asia-Pacific[China, Southeast Asia, India, Japan, Korea, Western Asia]
Europe[Germany, UK, France, Italy, Russia, Spain, Netherlands, Turkey, Switzerland]
North America[United States, Canada, Mexico]
Middle East & Africa[GCC, North Africa, South Africa]
South America[Brazil, Argentina, Columbia, Chile, Peru]

The research provides answers to the following key questions:
• What is the estimated growth rate and market share and size of the RNAi for Therapeutic market for the forecast period 2021 - 2025?
• What are the driving forces in the RNAi for Therapeutic market for the forecast period 2021 - 2025?
• Who are the prominent market players and how have they gained a competitive edge over other competitors?
• What are the market trends influencing the progress of the RNAi for Therapeutic industry worldwide?
• What are the major challenges and threats restricting the progress of the industry?
• What opportunities does the market hold for the prominent market players?